Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 2Dermatologic 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Lymphoma 11Lymphoma, Non-Hodgkin 10Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hodgkin Disease 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Hematologic Neoplasms 5Burkitt Lymphoma 5Neuroblastoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Neoplasm Metastasis 3Myelodysplastic Syndromes 3Melanoma 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Waldenstrom Macroglobulinemia 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Mycosis Fungoides 2Lymphoma, T-Cell 2

Interventions

Nivolumab 2Specimen Handling 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × Ipilimumab × Lymphoid × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡